Effect of Trifluoperazine in treatment of COVID-19

Phase 3

Recruiting

Conditions: U07.1
COVID-19 disease.
Pneumonia due to SARS-associated coronavirus

Registration Number: IRCT20200408046992N1

Lead Sponsor: Birjand University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 70

Inclusion Criteria

Patients with laboratory-confirmed COVID 19 infection with Real Time PCR and patients with evidence of lung involvement in CT Scan
Willing to provide informed consent
Age older than 12 years.
Patients admitted to specialized COVID-19 ward
Patients without Known severe allergy to trifluoperazine perazin and other phenothiazines such as cholorphenothiazines
Patients older than age 65 years are included if they do not suffer from Dementia-Related Psychosis

Exclusion Criteria

Patient With a Liver Disorder
Patients with bacterial or viral infection
Pregnant women
Patients with benign prostatic hyperplasia (BPH)
Patients with intestinal obstruction
Patients with blood disorders or bone marrow failure
Coma patients and patients with central nervous system weakness

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determining the efficacy of trifluoprazine in improving the Clinical manifestations of patients with confirmed COVID-19 infection by recording the patient's clinical parameters including 7 clinical parameters of respiration number, Blood Oxigen Saturation, oxygen support, temperature, heart rate, systolic blood pressure and Awareness level, assessment of lung involvement with Chest CT-Scan, measurement of c-reactive protein on treatment days, measurement of CBC indicators and biochemical factors such as urea and creatinine. Timepoint: Check of the patient's clinical condition and blood sampling of patients on days 1-14 in the hospital and also on the 28th day after the onset of the disease. Method of measurement: Measuring CBC indicators and biochemical factors using an autoanalyzer and examining heart function using EKG,Measurement of other factors using a thermometer and blood pressure monitor and patient bedside examinations.

Secondary Outcome Measures